Morgan Stanley Sangamo Therapeutics, Inc Transaction History
Morgan Stanley
- $1.35 Trillion
- Q3 2024
A detailed history of Morgan Stanley transactions in Sangamo Therapeutics, Inc stock. As of the latest transaction made, Morgan Stanley holds 352,747 shares of SGMO stock, worth $433,878. This represents 0.0% of its overall portfolio holdings.
Number of Shares
352,747
Previous 781,397
54.86%
Holding current value
$433,878
Previous $281,000
7.83%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding SGMO
# of Institutions
112Shares Held
56.7MCall Options Held
576KPut Options Held
1.17M-
Wasatch Advisors Inc Salt Lake City, UT19.4MShares$23.9 Million0.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.6MShares$11.8 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny4.85MShares$5.97 Million0.01% of portfolio
-
Black Rock Inc. New York, NY4.7MShares$5.78 Million0.0% of portfolio
-
Marshall Wace, LLP London, X02.35MShares$2.9 Million0.0% of portfolio
About SANGAMO THERAPEUTICS, INC
- Ticker SGMO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 156,552,992
- Market Cap $193M
- Description
- Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucle...